Achieves Robust Financial Performance with 74% Gross Margin and Strategic Public Offering, Bolstering Resources for Continued Growth and Innovation. Elevai Enfinity™ Clinical Trials Showcase Breakthroughs in Skin Firmness, Tone, and Wrinkle Reduction, Reinforcing Leadership in Aesthetic Innovation. Elevai Biosciences Expands Patent Portfolio with EL-22, a Myostatin-Targeting Treatment for Obesity, Addressing Muscle Preservation in Weight Management

NEWPORT BEACH, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a leader in medical aesthetics, announced today that it is has amended and restated the Offer to Exchange, including extending the expiration date, of its previously announced offer (the “Offer”) to holders of the Company’s outstanding Common

NEWPORT BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- EL-22 is a novel myostatin asset for the potential treatment of obesity in combination with existing GLP-1 medicines The Investigational New Drug application is planned for submission to the U.S. Food and Drug Administration (“FDA”) in 2025 Muscle wasting is a common side effect of popular

Preclinical results of EL-32 demonstrated statistically significant increases in grip strength, motor function and body composition in aged C57BL/6J mouse model. Elevai believes that EL-32 has the potential to treat obesity in combination with popular weight loss therapeutics, including GLP-1 receptor agonists, by preserving muscle mass while decreasing fat mass. Elevai plans to conduct additional

NEWPORT BEACH, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) ("Elevai" or the "Company"), a leader in medical aesthetics, today announced the commencement of an offer to exchange up to 15,000,000 shares of its currently issued and outstanding common stock, par value $0.0001 per share (the “Common Stock”) for up to 15,000,000 shares

Filed two patent applications for lead candidate EL-22, covering muscle loss in obese patients as a monotherapy and in combination with GLP-1 receptor agonists Elevai Biosciences patent portfolio now includes 4 patent applications and 5 issued patents that provide adequate protection in focus markets NEWPORT BEACH, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ:

In Collaboration with Renowned Aesthetic Medicine Expert Dr. Jennifer Pearlman, Elevai’s Study Will Investigate the Impact of Combining Exosome Skincare with Advanced Energy-Based Treatments for Optimal Skin Rejuvenation As the Global Energy-Based Aesthetic Device Market Is Projected to Reach $5.60 Billion by 2030, Elevai’s Study Seeks to Unlock the Full Potential of Combining Exosome Skincare

NEWPORT BEACH, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today announced that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by

Case Studies Highlight Potential of Elevai Exosome Technology in Melasma Care When Used with Laser Therapy. Early Results Show Synergistic Effects of Elevai Exosomes™ and Laser Treatments for Melasma Improvement, With No Recurrence After Six Months. NEWPORT BEACH, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering

On Going Research Study Demonstrates Reversal of Hair Thinning and Inflammation with Elevai Exosomes™. Ongoing Research to Combine Exosome and Mitochondrial Technology for Enhanced Scalp and Hair Vitality. NEWPORT BEACH, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) --  Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today announced data results from

“One of the Biggest Innovations in Hair Loss We’ve Seen in Twenty-Five Years” - BosleyMD® Teams With Start-up Yuva Biosciences in National Launch of Breakthrough Technology1 Elevai Labs and Yuva Biosciences Join Forces for Breakthrough in Hair and Scalp Care Technology NEWPORT BEACH, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB)

NEWPORT BEACH, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announces the completion of a clinical study examining the effectiveness of Elevai exosomes on facial appearance. The data, pending peer review, from the clinical study was internally reviewed by the Company,

Preliminary data from the research study in partnership with Dalhousie University demonstrates that Elevai’s hUMSC derived exosomes (“ELEVAI exosomes™”) contain over 800 proteins that are associated with wound healing, immunomodulation and remodeling of the skin’s extracellular matrix (“ECM”). ELEVAI exosomes™ protein profile detected as part of this study was statistically significant and notably enriched compared to

NEWPORT BEACH, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today reported financial results for the second quarter ended June 30, 2024 and provided a business update. Financial Results for the Three and Six Months Ended June 30, 2024 Revenue increased to

Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme. Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator. Dr. Shirihai is a renowned researcher regularly invited as a keynote speaker at annual scientific

Elevai is showcasing its new S-Series product line at The Aesthetic Show in Las Vegas, NV. Elevai's hair and scalp solutions combine the power of Exosomes with advanced Mitochondrial Technology. NEWPORT BEACH, Calif., June 28, 2024 (GLOBE NEWSWIRE) --  ELEVAI LABS, INC. (NASDAQ: ELAB), a pioneering force in medical aesthetics, is excited to announce the

NEWPORT BEACH, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- ELEVAI LABS, INC., (NASDAQ: ELAB) a pioneering force in medical aesthetics, is excited to announce Elevai Skincare’s participation in The Aesthetic Show, taking place on June 27-30, 2024 at the Wynn Las Vegas. The company will be showcasing its latest advancements at Booth #511 and unveiling the

NEWPORT BEACH, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity’s pressing issue of preserving muscle while on weight

NEWPORT BEACH, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announced that Chief Executive Officer Jordan R. Plews, PhD has been invited back and will be presenting at the Beauty Through Science conference in Stockholm, Sweden on Thursday May 30, 2024.

NEWPORT BEACH, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announced that Chief Executive Officer Dr. Jordan R. Plews, PhD will be presenting at the Los Angeles Bioscience Ecosystem Summit Twenty 24 (“LA-BEST”) conference on Thursday May 23, 2024. LA-BEST is the

NEWPORT BEACH, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today reported financial results for the first quarter ended March 31, 2024. Elevai Labs CEO, Jordan R. Plews, PhD stated, "This quarter, Elevai Labs has demonstrated remarkable year-over-year revenue growth while

Preclinical results of EL-22 from a 2022 study demonstrated physiological (serum creatine kinase level), physical (body weight change), and functional (rotarod test) improvements in the dystrophic features of mdx mice, a mouse model of Duchenne muscular dystrophy (DMD)1. Elevai believes that EL-22 has the potential to treat obesity in combination with popular weight loss therapeutics, including GLP-1

Elevai Labs established two subsidiaries: Elevai Biosciences, Inc., and Elevai Skincare, Inc. Elevai Biosciences will focus on acquiring and developing biopharmaceutical technologies with initial focus on the development of EL-22 and EL-32, the lead assets targeting indications associated with obesity. Elevai Skincare will continue commercializing exosome skincare technologies for the medical dispensed skincare market. NEWPORT

Agreement adds two drug candidates to product pipeline consisting of (i) “EL-22”, a clinical stage engineered probiotic expressing myostatin, and (ii) “EL-32”, a preclinical engineered probiotic expressing dual myostatin & activin-A. Exclusive license covers global rights excluding South Korea. Clinical and preclinical data supports advancing EL-22, a novel investigational myostatin asset for the treatment of

Five international distribution agreements signed to date Cumulative contracted minimum purchase requirements of $4.9M in the first five years Up to five additional international distribution agreements in discussion NEWPORT BEACH, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- ELEVAI Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a medical aesthetic company specializing in physician-dispensed skincare, announces significant strides in global distribution and highlights

-  Taiwan is ELEVAI’s third Asian contract for exosomes distribution after adding the Philippines in August of 2023 and Vietnam in May 2023-  Asia-Pacific represents a combined $13 Billion prestige skincare and luxury haircare market4,5 -  Immediate access to 40 specialty hair treatment clinics and four (4) high-end medical aesthetic clinics Newport Beach, CA –April,

Company reports record annual revenues of $1.71 Million for 2023, up 123.5% over the previous year Company reports record Q4 2023 revenues of $698,591, up 403% from Q4 2022  NEWPORT BEACH, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB), a medical aesthetic company specializing in physician-dispensed skincare, today reported financial results

ELEVAI Physician-Dispensed Skincare Now Available Direct to Consumers Newport Beach, CA – March, 18th 2023 – ELEVAI LABS, INC., (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skin care, is proud to announce the launch of its online E-commerce portal. The new E-commerce portal serves as a business-to-business (B2B) extension of the Company’s existing

Utility Patent Covers the formulation for ELEVAI’s flagship exosome-based skin care products Newport Beach, CA – January 24, 2023 - ELEVAI LABS, INC., (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skincare, is pleased to announce today that the United States Patent & Trademark Office (USPTO) issued US Patent No. 11,878,038, entitled “Exosome-based Skincare Product”

Newport Beach, CA – January, 17 2023 - ELEVAI LABS, INC., (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skincare, today announced certain preliminary, unaudited management-prepared financial results for the fiscal year ended December 31, 2023. These results are based on the most current information available to management, are unaudited, and subject to the completion of the

ELEVAI Labs to commercialize use of proprietary technology designed to produce high-quality, cGMP grade mesenchymal stromal cells at lower-costNewport Beach, CA – January 16, 2024 - Elevai Labs, Inc. (Nasdaq: ELAB) a medical aesthetic company specializing in physician-dispensed skincare is pleased to announce it has signed an exclusive, worldwide manufacturing and processing technology licensing agreement

Newport Beach, CA – January, 2 2023 - ELEVAI LABS, INC., (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skincare, announces participation in three aesthetic industry conferences in the first quarter of 2024. 1. Octane Aesthetic Technology Forum (ATF) in Newport Beach, California (January 24-25, 2024): ELEVAI's Third Consecutive Year as a Corporate Sponsor ELEVAI

Company Records Record Quarterly Revenues For Immediate Release Newport Beach, CA – December 11, 2023 – Elevai Labs Inc. (NASDAQ: ELAB), a medical aesthetic company specializing in physician-dispensed skincare, today reported financial results for its Q3 2023 fiscal quarter, ended September 30, 2023. “We are proud to announce a record setting quarter for Elevai marked by exceptional

Newport Beach, CA - December 7th, 2023 - Elevai Labs, Inc. (Nasdaq: ELAB) a medical aesthetic company specializing in physician-dispensed skincare is pleased to announce its new partnership with Skin Sana Ltd. a Serbian corporation and premier luxury skincare distributor based in Belgrade covering territories that include Serbia, Albania, North Macedonia, Kosovo and Bosnia-Herzegovina. This

Newport Beach, CA - November 29th, 2023 - Elevai Labs, Inc. (Nasdaq: ELAB) a medical aesthetic company specializing in physician-dispensed skincare, today announced that they have signed a licensing agreement with Yuva Biosciences, Inc. to research and develop means to incorporate Yuva Bioscience’s mitochondrial research with ELEVAI’s PREx™ (Precision Regenerative Exosome Technology™) to potentially develop topical

Newport Beach, CA – November 24, 2023 - ELEVAI LABS, INC. (Nasdaq: ELAB), a medical aesthetic company specializing in physician-dispensed skincare, today announced the closing of its previously announced initial public offering of 1,500,000 shares of common stock at a public offering price of $4.00 per share for total gross proceeds of $6,000,000, before deducting

Newport Beach, CA - November 20, 2023 – Elevai Labs, Inc., a medical aesthetic company specializing in physician-dispensed skincare, today announced the pricing of its initial public offering. The Offering consists of 1,500,000 shares of common stock at a public offering price of $4.00 per share, for total gross proceeds of $6,000,000 before deducting underwriting

Newport Beach, CA – August 1, 2023 – ELEVAI Labs, Inc, a medical aesthetic biotechnology company focused on physician-dispensed skincare and leader in exosome research and development, is pleased to announce its new partnership with Dmark Multisales Corporation, a prominent marketing and distribution company based in the Philippines. This strategic collaboration will see Dmark Multisales Corp.

Patented Exosome Skincare Line Now Available in the MENA Region Newport Beach, CA – June 8, 2023 - ELEVAI Labs Inc., a medical aesthetic biotechnology company specializing in physician-dispensed skincare, is pleased to announce its new international distributor agreement with Central Circle Company W.L.L in Kuwait. This strategic partnership marks ELEVAI Labs' expansion into the

Newport Beach, CA - May 18, 2023 - ELEVAI Labs Inc., a medical aesthetic biotechnology company specializing in physician-dispensed skincare, proudly announces COSBEAUTY Ltd., a subsidiary of Viet Can Trading and Service Co., Ltd, as the exclusive distributor of ELEVAI Skincare products in Vietnam, expanding the international footprint of its exosome-based cosmetic skincare products. The ELEVAI E-Series™ product range, a pre-and

NEWPORT BEACH, CA – April 26, 2023 – ELEVAI LABS, INC., a medical aesthetic biotechnology company specializing in physician-dispensed skincare, is pleased to report a stem cell exosome research partnership with Dr. Stanislav Sokolenko’s Lab at Dalhousie University and a non-repayable Grant from the Mitacs Accelerate Grants Program (“Mitacs”). Mitacs is an organization that funds

NEWPORT BEACH, CA – April 5, 2023 – ELEVAI LABS, INC., a science-based, data-driven aesthetic skincare company, will launch its revolutionary core technology platform, PREx™ (Precision Regenerative Exosome Technology™) from The American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting in Phoenix on April 13th. Co-Founded by Dr. Jordan Plews, a Stanford-trained scientist with

ELEVAI and EVOLVE To Celebrate New Partnership During AMWC Conference North America Newport Beach, CA - February 21, 2023 - ELEVAI LABS, INC., a medical aesthetic biotechnology company specializing in physician-dispensed skincare, proudly announces EVOLVE Medical Inc. as the exclusive distributor of ELEVAI Skincare products in Canada. The ELEVAI E-Series™ product range, a pre-and post-procedure skincare system developed with a proprietary stem

Former Evolus and Allergan Executive to Support the Company's Mission of Leading the Regenerative Skincare Market Newport Beach, CA - February 7, 2023 - ELEVAI LABS, INC., a medical aesthetic biotechnology company specializing in physician-dispensed skincare, proudly announces the addition of Crystal Muilenburg as an independent member of the company’s Board of Directors.  Crystal brings

ELEVAI LABS RETURNS TO INDUSTRY-LEADING OCTANE AESTHETICS TECH FORUM “People’s Choice Award” Winner Presents Groundbreaking Exosome Technology Newport Beach, CA - January 17, 2023 - ELEVAI LABS, INC., a medical aesthetic biotechnology company specializing in regenerative skincare, returns to the prestigious Octane Aesthetics Tech Forum on January 27 at the Balboa Bay Resort in Newport Beach,

NEWPORT BEACH, Calif., Nov. 29, 2022 /PRNewswire/ -- ELEVAI LABS, INC., a medical aesthetic biotechnology company specializing in regenerative skincare, proudly announces that cosmetic industry veteran James R. Headley joins the team as a Strategic Advisor. James R. Headley Mr. Headley, previously CEO of ZO Skin Health, will play an active role in supporting the ELEVAI management team as it

Co-Founder & CEO Jordan R. Plews, Ph.D. Presents Key Considerations For an Emerging New Class of Regenerative Skincare NEWPORT BEACH, Calif., Nov. 1, 2022 /PRNewswire/ -- ELEVAI LABS, INC., a medical aesthetic biotechnology company specializing in regenerative skincare, announces its sponsorship and participation in the upcoming Global Aesthetics Conference taking place November 3-5 in Miami. The Future of Skincare is Now A new era

- New buildout of GLP lab space with access to adjacent cGMP-certified lab marks 3rd expansion for Company in 2 years- New facility allows ELEVAI to culture its proprietary exosomes for manufacture at scale- Company intends to further double its lab space and headcount by the end of 2023 to satisfy growing demand and meet the company's market share

Chris Kraneiss DAVIS, Calif., Aug. 17, 2022 /PRNewswire/ -- ELEVAI LABS, INC., ("ELEVAI" or the "Company") a science-based, data-driven regenerative aesthetic skincare company is pleased to announce the appointment of industry veteran Chris Kraneiss as Chief Commercial Officer. Mr. Kraneiss holds a proven track record of building successful medical aesthetic businesses within top globally recognized brands. Mr. Kraneiss

"THE KOL MEETING FOR KOL'S" DAVIS, Calif., June 6, 2022 /PRNewswire/ -- ELEVAI LABS, INC., ("ELEVAI" or the "Company") a science-based, data-driven regenerative aesthetic skincare company is pleased to announce that Co-Founder and CEO Dr. Jordan Plews has been selected to speak at the world-renowned Beauty Through Sciences Symposium as a Stem Cell Exosome Key

DAVIS, Calif., May 23, 2022 /PRNewswire/ — ELEVAI LABS, INC., (“ELEVAI” or the “Company”) a science-based, data-driven regenerative aesthetic skincare company is pleased to announce it has retained Univest Securities, LLC for investment banking and advisory services.About Univest Securities, LLC Registered with FINRA since 1994, Univest Securities, LLC provides a wide variety of financial services

DAVIS, Calif., April 29, 2022 /PRNewswire/ — ELEVAI LABS, INC., (“ELEVAI” or the “Company”) a science-based, data-driven regenerative aesthetic skincare company is pleased to announce the appointment of industry expert Brenda Buechleras Chief Marketing and Brand Advisor. Ms. Buechler has an extensive and successful career that spans over 23 years in director and leadership roles

DAVIS, Calif., Aug. 17, 2022 /PRNewswire/ — ELEVAI LABS, INC., (“ELEVAI” or the “Company”) a science-based, data-driven regenerative aesthetic skincare company is pleased to announce the appointment of industry veteran Chris Kraneiss as Chief Commercial Officer. Mr. Kraneiss holds a proven track record of building successful medical aesthetic businesses within top globally recognized brands. Mr.

DAVIS, Calif., Jan. 25, 2022 /PRNewswire/ — ELEVAI LABS, INC., (“ELEVAI” or the “Company”) a biotech company leveraging the power of human stem cell exosomes to create next-generation topical skincare products, is pleased to announce that the company has won the LaunchPad SBDC People’s Choice Award at the 2022 Octane Aesthetics Tech Summit (“ATS”) held

DAVIS, Calif., Jan. 21, 2022 /PRNewswire/ — ELEVAI LABS, INC., (“ELEVAI” or the “Company”) a biotech company leveraging the power of human stem cell exosomes to create next-generation topical skincare products, is pleased to announce that it has signed a non-exclusive global distributor and trademark license agreement with leading Australian headquartered aesthetic device company DermapenWorld™

Aesthetics Tech Summit in Newport Beach, California. Jan 06 2022DAVIS, CALIFORNIA, Jan 06, 2022, ELEVAI LABS, INC., (“ELEVAI” or the “Company“) a biotech company leveraging the power of human stem cell exosomes to create next-generation topical skincare products, is pleased to announce that company co-founder and CEO, Jordan Plews, Ph.D., has been invited to present

DAVIS, CALIFORNIA, Dec 21, 2021 – ELEVAI Labs, Inc. (“ELEVAI”) is pleased to announce the much anticipated launch of its E-SERIES™ line of products. The E-SERIES is our post-treatment skincare line developed specifically for use following in-office aesthetic procedures. ELEVAI’s E-SERIES product line includes skincare formulations to support and enhance the results of in-office aesthetic